Page last updated: 2024-11-13

carolacton

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

carolacton: damages biofilms; isolated from Sorangium cellulosum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID56935649
CHEMBL ID4571710
CHEBI ID188515
MeSH IDM0551624

Synonyms (5)

Synonym
CHEBI:188515
(e,3r,4r,6r)-8-[(2s,3s,7r,8e,10r,11r)-10,11-dihydroxy-3,7-dimethyl-12-oxo-1-oxacyclododec-8-en-2-yl]-3-methoxy-4,6-dimethyl-5-oxonon-7-enoic acid
carolacton
c3r ,
CHEMBL4571710

Research Excerpts

Overview

Carolacton is a newly identified secondary metabolite causing altered cell morphology and death of Streptococcus mutans biofilm cells.

ExcerptReferenceRelevance
"Carolacton is a newly identified secondary metabolite causing altered cell morphology and death of Streptococcus mutans biofilm cells. "( Construction and verification of the transcriptional regulatory response network of Streptococcus mutans upon treatment with the biofilm inhibitor carolacton.
Dobler, IW; He, FQ; Reck, M; Sudhakar, P; Wagner-Döbler, I; Wang, W; Zeng, AP, 2014
)
2.04

Treatment

ExcerptReferenceRelevance
"Carolacton treatment caused a reduction in membrane potential, but not membrane integrity, and transcriptome analysis revealed compensatory reactions of the cell."( The biofilm inhibitor Carolacton inhibits planktonic growth of virulent pneumococci via a conserved target.
Bergmann, S; Donner, J; Kirschning, A; Müller, R; Reck, M; Wagner-Döbler, I, 2016
)
1.47
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
terpene lactone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1557221Antibiofilm activity against Streptococcus mutans assessed as decrease in biofilm viability at 0.053 to 53 uM by LIVE/DEAD staining based assay relative to control2019MedChemComm, Jul-01, Volume: 10, Issue:7
Targeting
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's18 (94.74)24.3611
2020's1 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.23 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index6.18 (4.65)
Search Engine Demand Index27.14 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (15.79%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (84.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]